Recite me link

1. In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide. Please provide the number of patients by treatment for the following disease modifying drugs.
Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Cladribine (Mavenclad)
Copaxone (glatiramer acetate)
Daclizumab (Zinbryta)
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Glatiramer acetate generic [eg Brabio]
Lemtrada (alemtuzumab)
Ocrevus (Ocrelizumab)
Peginterferon beta-1a (Plegridy)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Ampyra (Fampyra)
2. For patients receiving Tysabri (natalizumab) what is the average waiting times to treatment (i.e. once diagnosed and natalizumab selected as DMT of choice, how long do patients wait for their treatment to start)?

Download response Multiple Sclerosis. 270918